Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.

ABSTRACT: The identification of molecular markers, useful for therapeutic decisions in pancreatic cancer patients, is crucial for advances in disease management. Gemcitabine, although a cornerstone of current therapy, has limited efficacy. RRM1 is a key molecule for gemcitabine efficacy and is also involved in tumor progression. We determined in situ RRM1 and excision repair cross complementation group 1 (ERCC1) protein levels in 68 pancreatic cancer patients. All had R0 resections without preoperative therapy. Protein levels were determined by automated quantitative analysis (AQUA), a fluorescence-based immunohistochemical method. The relationship between protein expressions and clinical outcomes, including response to gemcitabine at the time of disease recurrence, was determined. Patients with hig

SUBMITTER: Akita H 

PROVIDER: S-EPMC3913371 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature